share_log

HC Wainwright Begins Coverage on IN8bio (NASDAQ:INAB)

HC Wainwright Begins Coverage on IN8bio (NASDAQ:INAB)

HC Wainwright开始对IN8Bio(纳斯达克：INAB)进行报道
kopsource ·  2022/09/03 02:41

HC Wainwright started coverage on shares of IN8bio (NASDAQ:INAB – Get Rating) in a research note published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $14.00 price objective on the stock.

据Marketbeat.com报道，HC Wainwright在周二发布的一份研究报告中开始报道IN8Bio(纳斯达克代码：INAB-GET Rating)的股票。该公司对该股发布了买入评级和14.00美元的目标价。

IN8bio Trading Down 16.6 %

IN8Bio股价下跌16.6%

Shares of IN8bio stock opened at $2.41 on Tuesday. The company's fifty day simple moving average is $2.22 and its 200-day simple moving average is $2.83. The company has a market cap of $45.40 million and a price-to-earnings ratio of -2.06. IN8bio has a 1 year low of $1.75 and a 1 year high of $9.50.

周二，IN8Bio的股票开盘报2.41美元。该公司的50日简单移动均线为2.22美元，200日简单移动均线为2.83美元。该公司市值为4540万美元，市盈率为-2.06倍。IN8Bio的一年低点为1.75美元，一年高位为9.50美元。

Get
到达
IN8bio
IN8Bio
alerts:
警报：

IN8bio (NASDAQ:INAB – Get Rating) last issued its earnings results on Friday, August 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.05). As a group, research analysts forecast that IN8bio will post -1.35 earnings per share for the current fiscal year.

IN8Bio(纳斯达克代码：INAB-GET Rating)最近一次发布财报是在8月12日(星期五)。该公司公布本季度每股收益(0.38美元)，低于普遍预期的(0.33美元)(0.05美元)。作为一个整体，研究分析师预测，IN8Bio本财年每股收益将达到1.35美元。

Insider Buying and Selling

内幕买卖

In other news, CEO William Tai-Wei Ho bought 26,315 shares of IN8bio stock in a transaction that occurred on Tuesday, August 16th. The stock was purchased at an average cost of $1.90 per share, with a total value of $49,998.50. Following the completion of the transaction, the chief executive officer now directly owns 2,315,745 shares in the company, valued at $4,399,915.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Emily Fairbairn acquired 789,473 shares of the business's stock in a transaction on Tuesday, August 16th. The stock was bought at an average cost of $1.90 per share, with a total value of $1,499,998.70. Following the completion of the acquisition, the director now owns 4,111,958 shares in the company, valued at $7,812,720.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO William Tai-Wei Ho acquired 26,315 shares of the business's stock in a transaction on Tuesday, August 16th. The shares were bought at an average cost of $1.90 per share, with a total value of $49,998.50. Following the completion of the acquisition, the chief executive officer now owns 2,315,745 shares of the company's stock, valued at approximately $4,399,915.50. The disclosure for this purchase can be found here. Insiders bought a total of 824,208 shares of company stock valued at $1,565,995 over the last ninety days. 35.80% of the stock is owned by company insiders.
在其他新闻方面，首席执行官何大伟在8月16日(星期二)的一笔交易中购买了26,315股IN8Bio股票。这只股票是以每股1.9美元的平均价格购买的，总价值为49,998.50美元。交易完成后，首席执行官现在直接拥有公司2,315,745股，价值4,399,915.50美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站获取。在相关新闻中，董事艾米丽·费尔贝恩在8月16日(星期二)的一笔交易中收购了该公司789,473股股票。这只股票的平均价格为每股1.9美元，总价值为1,499,998.70美元。收购完成后，董事现在拥有该公司4,111,958股，价值7,812,720.20美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在美国证券交易委员会网站上查阅。此外，首席执行官何大伟在8月16日星期二的一次交易中购买了26,315股该公司的股票。这些股票的平均价格为每股1.9美元，总价值为49,998.50美元。收购完成后，首席执行官现在拥有2,315,745股公司股票，价值约4,399,915.50美元。此次收购的披露信息可在此处找到。在过去的90天里，内部人士总共买入了824,208股公司股票，价值1,565,995美元。35.80%的股份由公司内部人士持有。

Institutional Inflows and Outflows

机构资金流入和流出

Hedge funds and other institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC bought a new position in shares of IN8bio during the fourth quarter valued at $44,000. BlackRock Inc. raised its holdings in shares of IN8bio by 70.8% in the first quarter. BlackRock Inc. now owns 16,334 shares of the company's stock valued at $54,000 after buying an additional 6,773 shares during the last quarter. Rock Creek Group LP raised its holdings in shares of IN8bio by 87.5% in the first quarter. Rock Creek Group LP now owns 86,032 shares of the company's stock valued at $299,000 after buying an additional 40,160 shares during the last quarter. Ensign Peak Advisors Inc bought a new position in shares of IN8bio in the fourth quarter valued at about $307,000. Finally, Sigma Planning Corp raised its holdings in shares of IN8bio by 241.8% in the first quarter. Sigma Planning Corp now owns 97,750 shares of the company's stock valued at $326,000 after buying an additional 69,150 shares during the last quarter. 12.98% of the stock is owned by institutional investors.

对冲基金和其他机构投资者最近改变了他们在该股的头寸。HighTower Advisors LLC在第四季度购买了IN8Bio的新头寸，价值44,000美元。贝莱德股份有限公司在第一季度增持了70.8%的IN8Bio股票。贝莱德股份有限公司现在持有该公司16,334股股票，价值54,000美元，该公司在上个季度又购买了6,773股。Rock Creek Group LP在第一季度增持了87.5%的IN8Bio股票。Rock Creek Group LP现在持有该公司86,032股股票，价值29.9万美元，上个季度又购买了40,160股。Ensign Peak Advisors Inc.在第四季度购买了IN8Bio的新头寸，价值约307,000美元。最后，西格玛规划公司在第一季度增持了241.8%的IN8Bio股票。西格玛规划公司目前持有97,750股该公司股票，价值326,000美元，此前该公司在上个季度又购买了69,150股票。该公司12.98%的股份由机构投资者持有。

About IN8bio

关于IN8Bio

(Get Rating)

(获取评级)

IN8bio, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.

IN8Bio，Inc.是一家临床阶段的生物技术公司，专注于治疗癌症的伽马-德尔塔T细胞疗法的发现、开发和商业化。它的主要候选产品包括INB-200，这是一种用于治疗胶质母细胞瘤和实体瘤的转基因自体伽马-德尔塔T细胞候选产品，目前处于第一阶段临床试验；以及INB-100，一种异基因产品候选产品，正在进行第一阶段临床试验，用于治疗接受造血干细胞移植的急性白血病患者。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on IN8bio (INAB)
  • Could Snap Stock Rebound As Management Restructures?
  • MarketBeat: Week in Review 8/29 – 9/2
  • Hormel Looks Cheap At These Levels
  • Lululemon Set To Soar Into September
  • Could Nike Stock be Oversold, but Still Overvalued?
  • 免费获取StockNews.com关于IN8Bio的研究报告(INAB)
  • 随着管理层重组，股市能否迅速反弹？
  • MarketBeat：回顾中的一周8/29-9/2
  • 霍梅尔在这些水平上看起来很便宜
  • 露露柠檬将飙升至9月
  • 耐克股票会被超卖，但仍被高估吗？

Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.

接受IN8Bio日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对IN8Bio和相关公司的最新新闻和分析师评级的每日简明摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发